Medite Cancer Diagnostics (Medite Cancer Diagnostics) Change In Prepaid Assets : $-0.52 Mil (TTM As of Sep. 2018)

View and export this data going back to . Start your Free Trial

What is Medite Cancer Diagnostics Change In Prepaid Assets?

Medite Cancer Diagnostics's Change In Prepaid Assets for the quarter that ended in Sep. 2018 was $-0.21 Mil. It means Medite Cancer Diagnostics's Prepaid Assets declined by $0.21 Mil from Jun. 2018 to Sep. 2018 .

Medite Cancer Diagnostics's Change In Prepaid Assets for the fiscal year that ended in Dec. 2017 was $-0.06 Mil. It means Medite Cancer Diagnostics's Prepaid Assets declined by $0.06 Mil from Dec. 2016 to Dec. 2017 .

Medite Cancer Diagnostics Change In Prepaid Assets Historical Data

The historical data trend for Medite Cancer Diagnostics's Change In Prepaid Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medite Cancer Diagnostics Change In Prepaid Assets Chart

Medite Cancer Diagnostics Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Change In Prepaid Assets

Get a 7-Day Free Trial

0.18

0.11

-0.03

0.10

-0.06

Medite Cancer Diagnostics Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Change In Prepaid Assets	Get a 7-Day Free Trial															-0.03	0.06	-0.26	-0.10	-0.21

Medite Cancer Diagnostics Change In Prepaid Assets Calculation

Change In Prepaid Assets is any increase or decrease between periods of the prepaid assets.

Change In Prepaid Assets for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.52 Mil.

Medite Cancer Diagnostics Change In Prepaid Assets Related Terms

Thank you for viewing the detailed overview of Medite Cancer Diagnostics's Change In Prepaid Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Medite Cancer Diagnostics (Medite Cancer Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medite Cancer Diagnostics Inc (OTCPK:MDIT) » Definitions » Change In Prepaid Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

4203 SouthWest 34th Street, Orlando, FL, USA, 32811

Website

http://www.medite-group.com

Medite Cancer Diagnostics Inc is a US-based company which specializes in the marketing and selling of MEDITE core products (instruments and consumables), manufacturing, development of new solutions in histology and cytology and marketing of molecular biomarkers. The company manufactures medical devices and consumables are for detection, risk assessment and diagnosis of cancerous and precancerous conditions and related diseases. Medite operates through the single segment for cancer diagnostics instruments and consumables for histology and cytology laboratories. It offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis.

Executives

Lewis William Austin Iv	director, 10 percent owner	201 E 87TH STREET, APT 5H, NEW YORK NY 10128
John H Abeles	director	2365 NW 41ST STREET BOCA RATON FL 33431
Joel S Kanter	director	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Clinton Severson	director	C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587

Medite Cancer Diagnostics (Medite Cancer Diagnostics) Headlines

No Headlines